Compare Shionogi & Co., Ltd. with Similar Stocks
Dashboard
1
Strong Long Term Fundamental Strength with an average Return on Equity (ROE) of 13.50%
- Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of 55.35
2
Positive results in Dec 25
3
With ROE of 12.84%, it has a very attractive valuation with a 2.06 Price to Book Value
4
Majority shareholders : FIIs
Stock DNA
Pharmaceuticals & Biotechnology
JPY 2,803,231 Million (Large Cap)
16.00
NA
0.00%
-0.14
12.84%
1.85
Revenue and Profits:
Net Sales:
147,719 Million
(Quarterly Results - Dec 2025)
Net Profit:
74,680 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-6.37%
0%
-6.37%
6 Months
21.86%
0%
21.86%
1 Year
34.25%
0%
34.25%
2 Years
-57.05%
0%
-57.05%
3 Years
-48.77%
0%
-48.77%
4 Years
-56.67%
0%
-56.67%
5 Years
-43.9%
0%
-43.9%
Shionogi & Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
8.96%
EBIT Growth (5y)
9.00%
EBIT to Interest (avg)
55.35
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.27
Sales to Capital Employed (avg)
0.33
Tax Ratio
15.55%
Dividend Payout Ratio
30.61%
Pledged Shares
0
Institutional Holding
0.03%
ROCE (avg)
17.59%
ROE (avg)
13.50%
Valuation key factors
Factor
Value
P/E Ratio
16
Industry P/E
Price to Book Value
2.06
EV to EBIT
18.00
EV to EBITDA
15.89
EV to Capital Employed
2.23
EV to Sales
6.26
PEG Ratio
1.00
Dividend Yield
NA
ROCE (Latest)
12.41%
ROE (Latest)
12.84%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Mildly Bullish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bearish
Bullish
Shareholding Snapshot : Dec 2025
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 1 Foreign Institutions (0.03%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ
Dec'25
Sep'25
Change(%)
Net Sales
147,719.00
113,184.00
30.51%
Operating Profit (PBDIT) excl Other Income
62,751.00
45,809.00
36.98%
Interest
1,611.00
1,825.00
-11.73%
Exceptional Items
0.00
0.00
Consolidate Net Profit
74,680.00
44,184.00
69.02%
Operating Profit Margin (Excl OI)
383.90%
359.20%
2.47%
USD in Million.
Net Sales
QoQ Growth in quarter ended Dec 2025 is 30.51% vs 13.43% in Sep 2025
Consolidated Net Profit
QoQ Growth in quarter ended Dec 2025 is 69.02% vs 12.29% in Sep 2025
Annual Results Snapshot (Consolidated) - Mar'25
Mar'25
Mar'24
Change(%)
Net Sales
438,268.00
435,081.00
0.73%
Operating Profit (PBDIT) excl Other Income
180,712.00
189,783.00
-4.78%
Interest
1,646.00
1,076.00
52.97%
Exceptional Items
-7,698.00
-21,200.00
63.69%
Consolidate Net Profit
169,534.00
160,575.00
5.58%
Operating Profit Margin (Excl OI)
364.60%
394.10%
-2.95%
USD in Million.
Net Sales
YoY Growth in year ended Mar 2025 is 0.73% vs 1.97% in Mar 2024
Consolidated Net Profit
YoY Growth in year ended Mar 2025 is 5.58% vs -12.97% in Mar 2024
About Shionogi & Co., Ltd. 
Shionogi & Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






